Decompensated liver disease due to portal hypertension leads to significant morbidity and mortality. Statins can modulate intrahepatic vascular tone, but the clinical significance remains uncertain.
Dr Wong and colleagues from Hong Kong determined the effects of statin use on the risk of liver decompensation and death among patients with chronic viral hepatitis.
The researchers conducted a population wide cohort study using a hospital based database from the Hong Kong Hospital Authority.
Adults with chronic viral hepatitis without prior liver decompensation were identified from 2000 to 2012 by International Classification of Diseases, Ninth Revision, Clinical Modification, diagnostic codes.
|A total of 69,184 patients with chronic viral hepatitis was identified|
|Alimentary Pharmacology & Therapeutics|
The team defined statin use as a cumulative defined daily dose of more than 28.
Landmark analysis was used to overcome immortal time bias.
Propensity score weighting was further performed to minimise baseline confounders.
The researchers' primary outcome was a composite of portal hypertension related liver decompensation events, with adjustment for death as a competing risk.
The team identified a total of 69,184 patients with chronic viral hepatitis for the 2-year landmark analysis.
After propensity score weighting of 23 baseline covariates, statin use was associated with a significant reduction in composite liver decompensation events, ascites, and a dose-dependent decrease in death relative to no statin use.
Dr Wong's team concluded, "Patients with chronic viral hepatitis who used statins have a reduced risk of liver decompensation and death compared to non-users in this propensity score weighted landmark analysis."